3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Triple Negative Breast Neoplasms
2
Neuroblastoma
2
Melanoma
2
Lung Neoplasms
2
Gliosarcoma
2
Glioblastoma
2
Unilateral Breast Neoplasms
1
Prostatic Neoplasms
1
Pathologic Complete Response
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Mesothelioma
1
Locally Advanced Pancreatic Adenocarcinoma
1
Leukemia, Plasma Cell
1
Leukemia, Myeloid, Acute
1
Inflammatory Breast Neoplasms
1
Ganglioneuroblastoma
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
5
Cyclophosphamide
4
fludarabine
3
Nivolumab
3
Ipilimumab
3
tislelizumab
2
Pemetrexed
2
Cisplatin
2
spartalizumab
1
sargramostim
1
ruxolitinib
1
obinutuzumab
1
naptumomab estafenatox
1
fludarabine phosphate
1
durvalumab
1
avelumab
1
UV1 vaccine
1
Radiotherapy, Intensity-Modulated
1
Cerebral Decortication
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Mesothelioma
×
sargramostim
×
Clear all
NCT04300244
2024-02-29
NIPU
Oslo University Hospital
Phase 2
Active not recruiting
118 enrolled